Nontuberculous mycobacteria in cystic fibrosis: Updates and the path forward

Pediatric Pulmonology

Volumn 52, Issue , 2017, Pages S29-S36

  Martiniano, Stacey L ^a   Davidson, Rebecca M ^b   Nick, Jerry A ^b  

^a University of Colorado Denver and Children s Hospital Colorado   (United States)

^b DEPARTMENT OF MEDICINE   (United States)

Author keywords

cystic fibrosis; mycobacteria; Mycobacterium abscessus; Mycobacterium avium; nontuberculous; transmission

Indexed keywords

AMIKACIN; AZITHROMYCIN; BEDAQUILINE; CEFOXITIN; CLARITHROMYCIN; CLOFAZIMINE; ETHAMBUTOL; IMIPENEM; IVACAFTOR; IVACAFTOR PLUS LUMACAFTOR; LINEZOLID; MACROLIDE; MINOCYCLINE; MOXIFLOXACIN; RIFAMPICIN; TIGECYCLINE;

ACID FAST BACTERIUM; ALLERGIC PNEUMONITIS; ATYPICAL MYCOBACTERIOSIS; ATYPICAL MYCOBACTERIUM; BACTERIUM ISOLATE; BRONCHIECTASIS; CONSENSUS DEVELOPMENT; CYSTIC FIBROSIS; CYTOPENIA; DISEASE TRANSMISSION; DYSPNEA; FOMITE; GENETIC SIMILARITY; HOST SUSCEPTIBILITY; HUMAN; LUNG BIOPSY; MYCOBACTERIUM ABSCESSUS; MYCOBACTERIUM AVIUM; MYCOBACTERIUM INTRACELLULARE; OPTIC NEURITIS; OROPHARYNX PAIN; PERIPHERAL NEUROPATHY; PHENOTYPE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; RESPIRATORY TRACT DISEASE; REVIEW; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; SPUTUM CULTURE; TRANSBRONCHIAL BIOPSY; UNITED STATES; WHOLE GENOME SEQUENCING; MICROBIOLOGY; TREATMENT OUTCOME;

CYSTIC FIBROSIS; HUMANS; MYCOBACTERIUM INFECTIONS, NONTUBERCULOUS; NONTUBERCULOUS MYCOBACTERIA; RISK FACTORS; TREATMENT OUTCOME;

EID: 85028949975     PISSN: 87556863     EISSN: 10990496     Source Type: Journal    
DOI: 10.1002/ppul.23825     Document Type: Review

References (76)

1. Qvist T, Pressler T, Hoiby N, Katzenstein TL. Shifting paradigms of nontuberculous mycobacteria in cystic fibrosis. Respir Res. 2014; 15:41.
2. Bar-On O, Mussaffi H, Mei-Zahav M, et al. Increasing nontuberculous mycobacteria infection in cystic fibrosis. J Cyst Fibros. 2015; 14:53–62.
3. Adjemian J, Olivier KN, Seitz AE, Holland SM, Prevots DR. Prevalence of nontuberculous mycobacterial lung disease in U.S. Medicare beneficiaries. Am J Respir Crit Care Med. 2012; 185:881–886.
4. Marras TK, Daley CL. Epidemiology of human pulmonary infection with nontuberculous mycobacteria. Clin Chest Med. 2002; 23:553–567.
5. Sermet-Gaudelus I, Le Bourgeois M, Pierre-Audigier C, et al. Mycobacterium abscessus and children with cystic fibrosis. Emerg Infect Dis. 2003; 9:1587–1591.
6. Roux AL, Catherinot E, Ripoll F, et al. Multicenter study of prevalence of nontuberculous mycobacteria in patients with cystic fibrosis in france. J Clin Microbiol. 2009; 47:4124–4128.
7. Aitken ML, Burke W, McDonald G, Wallis C, Ramsey B, Nolan C. Nontuberculous mycobacterial disease in adult cystic fibrosis patients. Chest. 1993; 103:1096–1099.
8. Valenza G, Tappe D, Turnwald D, et al. Prevalence and antimicrobial susceptibility of microorganisms isolated from sputa of patients with cystic fibrosis. J Cyst Fibros. 2008; 7:123–127.
9. Qvist T, Gilljam M, Jonsson B, et al. Epidemiology of nontuberculous mycobacteria among patients with cystic fibrosis in Scandinavia. J Cyst Fibros. 2015; 14:46–52.
10. Adjemian J, Olivier KN, Prevots DR. Nontuberculous mycobacteria among cystic fibrosis patients in the United States: screening practices and environmental risk. Am J Respir Crit Care Med. 2014; 190:581–586.
11. Cystic_Fibrosis_Foundation_Patient_Registry. 2015 Annual Data Report Bethesda, MD, 2016.
12. Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007; 175:367–416.
13. Floto RA, Olivier KN, Saiman L, et al. US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis. Thorax. 2016; 71:1i1–i22.
14. Martiniano SL, Sontag MK, Daley CL, Nick JA, Sagel SD. Clinical significance of a first positive nontuberculous mycobacteria culture in cystic fibrosis. Ann Am Thorac Soc. 2014; 11:36–44.
15. Martiniano SL, Nick JA. Nontuberculous mycobacterial infections in cystic fibrosis. Clin Chest Med. 2015; 36:101–115.
16. Ballarino GJ, Olivier KN, Claypool RJ, Holland SM, Prevots DR. Pulmonary nontuberculous mycobacterial infections: antibiotic treatment and associated costs. Respir Med. 2009; 103:1448–1455.
17. Ramsey BW, Davies J, McElvaney NG, et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med. 2011; 365:1663–1672.
18. Wainwright CE, Elborn JS, Ramsey BW. Lumacaftor-Ivacaftor in patients with cystic fibrosis homozygous for phe508del CFTR. N Engl J Med. 2015; 373:1783–1784.
19. Kim RD, Greenberg DE, Ehrmantraut ME, et al. Pulmonary nontuberculous mycobacterial disease: prospective study of a distinct preexisting syndrome. Am J Respir Crit Care Med. 2008; 178:1066–1074.
20. Ziedalski TM, Kao PN, Henig NR, Jacobs SS, Ruoss SJ. Prospective analysis of cystic fibrosis transmembrane regulator mutations in adults with bronchiectasis or pulmonary nontuberculous mycobacterial infection. Chest. 2006; 130:995–1002.
21. Catherinot E, Roux AL, Vibet MA, et al. Mycobacterium avium and Mycobacterium abscessus complex target distinct cystic fibrosis patient subpopulations. J Cyst Fibros. 2013; 12: 74–80.
22. Roux A-L, Catherinot E, Ripoll F, et al. Multicenter study of prevalence of nontuberculous mycobacteria in patients with cystic fibrosis in france. J Clin Microbiol. 2009; 47:4124–4128.
23. Rodman DM, Polis JM, Heltshe SL, et al. Late diagnosis defines a unique population of long-term survivors of cystic fibrosis. Am J Respir Crit Care Med. 2005; 171:621–626.
24. Feazel LM, Baumgartner LK, Peterson KL, Frank DN, Harris JK, Pace NR. Opportunistic pathogens enriched in showerhead biofilms. Proc Natl Acad Sci USA. 2009; 106:16393–16399.
25. Falkinham JO, 3rd. Nontuberculous mycobacteria from household plumbing of patients with nontuberculous mycobacteria disease. Emerg Infect Dis. 2011; 17:419–424.
26. Ovrutsky AR, Chan ED, Kartalija M, et al. Cooccurrence of free-living amoebae and nontuberculous mycobacteria in hospital water networks, and preferential growth of Mycobacterium avium in Acanthamoeba lenticulata. Appl Environ Microbiol. 2013; 79:3185–3192.
27. Honda JR, Hasan NA, Davidson RM, et al. Environmental nontuberculous mycobacteria in the hawaiian islands. PLoS Negl Trop Dis. 2016; 10:e0005068.
28. Zhao X, Epperson LE, Hasan NA, et al. Complete genome sequence of mycobacterium avium subsp. Hominissuis strain H87 isolated from an indoor water sample. Genome Announc. 2017; 5:[Epub ahead of print].
29. Primm TP, Lucero CA, Falkinham JO, 3rd. Health impacts of environmental mycobacteria. Clin Microbiol Rev. 2004; 17:98–106.
30. De Groote MA, Pace NR, Fulton K, Falkinham JO, 3rd. Relationships between mycobacterium isolates from patients with pulmonary mycobacterial infection and potting soils. Appl Environ Microbiol. 2006; 72:7602–7606.
31. Nishiuchi Y, Maekura R, Kitada S, et al. The recovery of Mycobacterium avium-intracellulare complex (MAC) from the residential bathrooms of patients with pulmonary MAC. Clin Infect Dis. 2007; 45:347–351.
32. Falkinham JO, 3rd, Iseman MD, de Haas P, van Soolingen D. Mycobacterium avium in a shower linked to pulmonary disease. J Water Health. 2008; 6:209–213.
33. Nishiuchi Y, Tamura A, Kitada S, et al. Mycobacterium avium complex organisms predominantly colonize in the bathtub inlets of patients’ bathrooms. Jpn J Infect Dis. 2009; 62:182–186.
34. Thomson R, Tolson C, Sidjabat H, Huygens F, Hargreaves M. Mycobacterium abscessus isolated from municipal water—a potential source of human infection. BMC Infect Dis. 2013; 13:241.
35. Aitken ML, Limaye A, Pottinger P, et al. Respiratory outbreak of Mycobacterium abscessus subspecies massiliense in a lung transplant and cystic fibrosis center. Am J Respir Crit Care Med. 2012; 185:231–232.
36. Bryant JM, Grogono DM, Greaves D, et al. Whole-genome sequencing to identify transmission of Mycobacterium abscessus between patients with cystic fibrosis: a retrospective cohort study. Lancet. 2013; 381:1551–1560.
37. Harris KA, Underwood A, Kenna DT, et al. Whole-genome sequencing and epidemiological analysis do not provide evidence for cross-transmission of mycobacterium abscessus in a cohort of pediatric cystic fibrosis patients. Clin Infect Dis. 2015; 60:1007–1016.
38. Tortoli E, Kohl TA, Trovato A, et al. Mycobacterium abscessus in patients with cystic fibrosis: low impact of inter-human transmission in Italy. Eur Respir J. 2017; 50:[Epub ahead of print].
39. Bryant JM, Grogono DM, Rodriguez-Rincon D, et al. Emergence and spread of a human-transmissible multidrug-resistant nontuberculous mycobacterium. Science. 2016; 354:751–757.
40. Davidson RM, Hasan NA, Reynolds PR, et al. Genome sequencing of Mycobacterium abscessus isolates from patients in the united states and comparisons to globally diverse clinical strains. J Clin Microbiol. 2014; 52:3573–3582.
41. Davidson RM, Hasan NA, de Moura VC, Duarte RS, Jackson M, Strong M. Phylogenomics of Brazilian epidemic isolates of Mycobacterium abscessus subsp. bolletii reveals relationships of global outbreak strains. Infect Genet Evol. 2013; 20:292–297.
42. Tettelin H, Davidson RM, Agrawal S, et al. High-level relatedness among Mycobacterium abscessus subsp. massiliense strains from widely separated outbreaks. Emerg Infect Dis. 2014; 20:364–371.
43. Everall I, Nogueira CL, Bryant JM, et al. Genomic epidemiology of a national outbreak of post-surgical Mycobacterium abscessus wound infections in Brazil. Microbial Genomics. 2017.
44. Malcolm KC, Caceres SM, Honda JR, et al. Mycobacterium abscessus displays fitness for fomite transmission. Appl Environ Microbiol. 2017. [Epub ahead of print].
45. Strong M, Davidson RM. Microbiology: bacterial transmission tactics. Nature. 2017; 543:495–496.
46. Martiniano SL, Nick JA, Daley CL. Nontuberculous mycobacterial infections in cystic fibrosis. Clin Chest Med. 2016; 37:83–96.
47. Esther CR, Jr., Esserman DA, Gilligan P, Kerr A, Noone PG. Chronic Mycobacterium abscessus infection and lung function decline in cystic fibrosis. J Cystic Fibrosis. 2010; 9:117–123.
48. Fauroux B, Delaisi B, Clement A, et al. Mycobacterial lung disease in cystic fibrosis: a prospective study. Pediatr Infect Dis J. 1997; 16:354–358.
49. Torrens JK, Dawkins P, Conway SP, Moya E. Non-tuberculous mycobacteria in cystic fibrosis. Thorax. 1998; 53:182–185.
50. Qvist T, Taylor-Robinson D, Waldmann E, et al. Comparing the harmful effects of nontuberculous mycobacteria and gram negative bacteria on lung function in patients with cystic fibrosis. J Cyst Fibros. 2016; 15:380–385.
51. Martiniano SL, Sagel SD, Daley C, Ellington S, Nick JA. Prospective evaluation of nontuberculous mycobacterial disease in cystic fibrosis (PREDICT) trial. Pediatr Pulmonol Suppl. 2015; 39:A297.
52. Waters V, Ratjen F. Antibiotic treatment for nontuberculous mycobacteria lung infection in people with cystic fibrosis. Cochrane Database Syst Rev. 2016; 12:CD010004.
53. Griffith DE, Brown-Elliott BA, Langsjoen B, et al. Clinical and molecular analysis of macrolide resistance in Mycobacterium avium complex lung disease. Am J Respir Crit Care Med. 2006; 174:928–934.
54. Moon SM, Park HY, Kim SY, et al. Clinical characteristics, treatment outcomes, and resistance mutations associated with macrolide-resistant Mycobacterium avium complex lung disease. Antimicrob Agents Chemother. 2016; 60:6758–6765.
55. Jarand J, Levin A, Zhang L, Huitt G, Mitchell JD, Daley CL. Clinical and microbiologic outcomes in patients receiving treatment for Mycobacterium abscessus pulmonary disease. Clin Infect Dis. 2011; 52:565–571.
56. DaCosta A, Jordan CL, Giddings O, Lin FC, Gilligan P, Esther CR Jr. Outcomes associated with antibiotic regimens for treatment of Mycobacterium abscessus in cystic fibrosis patients. J Cyst Fibros. 2017; 16:483–487.
57. Koh WJ, Jeong BH, Kim SY, et al. Mycobacterial characteristics and treatment outcomes in Mycobacterium abscessus lung disease. Clin Infect Dis. 2017; 64:309–316.
58. Koh WJ, Jeon K, Lee NY, et al. Clinical significance of differentiation of Mycobacterium massiliense from Mycobacterium abscessus. Am J Respir Crit Care Med. 2011; 183:405–410.
59. Lyu J, Kim BJ, Song JW, et al. A shorter treatment duration may be sufficient for patients with Mycobacterium massiliense lung disease than with Mycobacterium abscessus lung disease. Respir Med. 2014; 108:1706–1712.
60. Roux AL, Catherinot E, Soismier N, et al. Comparing Mycobacterium massiliense and Mycobacterium abscessus lung infections in cystic fibrosis patients. J Cyst Fibros. 2015; 14:63–69.
61. Renna M, Schaffner C, Brown K, et al. Azithromycin blocks autophagy and may predispose cystic fibrosis patients to mycobacterial infection. J Clin Invest. 2011; 121:3554–3563.
62. Gillespie SH, Billington O. Activity of moxifloxacin against mycobacteria. J Antimicrob Chemother. 1999; 44:393–395.
63. Koh WJ, Hong G, Kim SY, et al. Treatment of refractory Mycobacterium avium complex lung disease with a moxifloxacin-containing regimen. Antimicrob Agents Chemother. 2013; 57:2281–2285.
64. Bermudez LE, Inderlied CB, Kolonoski P, et al. Activity of moxifloxacin by itself and in combination with ethambutol, rifabutin, and azithromycin in vitro and in vivo against Mycobacterium avium. Antimicrob Agents Chemother. 2001; 45:217–222.
65. Jarand J, Davis JP, Cowie RL, Field SK, Fisher DA. Long term follow up of Mycobacterium avium complex lung disease in patients treated with regimens including clofazimine and/or rifampin. Chest. 2015.
66. Martiniano SL, Wagner BD, Levin A, Nick JA, Sagel SD, Daley CL. Safety and effectiveness of clofazimine for primary and refractory nontuberculous mycobacterial infection. Chest. 2017. [Epub ahead of print].
67. Davis KK, Kao PN, Jacobs SS, Ruoss SJ. Aerosolized amikacin for treatment of pulmonary Mycobacterium avium infections: an observational case series. BMC Pulm Med. 2007; 7:[Epub ahead of print].
68. Olivier KN, Shaw PA, Glaser TS, et al. Inhaled amikacin for treatment of refractory pulmonary nontuberculous mycobacterial disease. Ann Am Thorac Soc. 2014; 11:30–35.
69. Olivier KN, Griffith DE, Eagle G, et al. Randomized trial of liposomal amikacin for inhalation in nontuberculous mycobacterial lung disease. Am J Respir Crit Care Med. 2017; 195:814–823.
70. Brown-Elliott BA, Philley JV, Griffith DE, Thakkar F, Wallace RJ Jr. In vitro susceptibility testing of bedaquiline against Mycobacterium avium complex. Antimicrob Agents Chemother. 2017; 61:[Epub ahead of print].
71. Winthrop KL, Ku JH, Marras TK, et al. The tolerability of linezolid in the treatment of nontuberculous mycobacterial disease. Eur Respir J. 2015; 45:1177–1179.
72. Alexander DC, Vasireddy R, Vasireddy S, et al. Emergence of mmpT5 variants during bedaquiline treatment of mycobacterium intracellulare lung disease. J Clin Microbiol. 2017; 55:574–584.
73. Philley JV, Wallace RJ Jr., Benwill JL, et al. Preliminary results of bedaquiline as salvage therapy for patients with nontuberculous mycobacterial lung disease. Chest. 2015; 148:499–506.
74. Kobashi Y, Matsushima T, Oka M. A double-blind randomized study of aminoglycoside infusion with combined therapy for pulmonary Mycobacterium avium complex disease. Respir Med. 2007; 101:130–138.
75. Jeon K, Kwon OJ, Lee NY, et al. Antibiotic treatment of Mycobacterium abscessus lung disease: a retrospective analysis of 65 patients. Am J Respir Crit Care Med. 2009; 180:896–902.
76. Nick JA, Sagel SD, Daley C, Ellington S, Martiniano SL. Prospective algorithm for treatment of nontuberculous mycobacterial disease in cystic fibrosis (PATIENCE) trial. Pediatr Pulmonol Suppl. 2015; 39:A297.